Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2021 | Diagnostic biomarkers and efficacious treatments are unmet needs in autoimmune encephalitis

Autoimmune encephalitis is a complex condition, with many aspects of causality and treatment incompletely understood. Divyanshu Dubey, MBBS, Mayo Clinic, Rochester, MN, discusses the main challenges currently faced in the field. These include improving diagnosis, as a lack of diagnostic biomarkers means a large percentage of patients are diagnosed based only on clinical judgement. Additionally, treating autoimmune encephalitis successfully with minimal side effects remains a challenge. This interview took place during the ACTRIMS Forum 2021.


Dr. Dubey has consulted for UCB, Immunovant and Astellas Pharma. All compensation for consulting activities is paid to Mayo Clinic. He has a patent pending for KLHL 11-IgG and LUZP4-IgG as markers of neurological autoimmunity and germ cell tumors.